A investment management firm based in China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries, including healthcare. The firm’s healthcare portfolio includes Chase Sun Pharmaceutical, Lisheng Pharma, Tasly Pharm, Furui Medical Science, Zhongxin Pharmaceutical, and Tianyao Medical Industry. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a Japan-based corporate with offices in Japan, China, India, and Silicon Valley makes seed, venture, and growth stage investments in companies in the life sciences space as well as other spaces like IT and cleantech. The firm typically makes equity investments in the range of $3-5M per portfolio company.

The firm primarily invests in life science companies based in the USA, but due to the firm’s global presence, the firm can also invest in companies based in China, Japan, India, and Europe. The firm has no current mandate for the number of allocations it plans to make in the space and will evaluate relevant opportunities as they surface.

The firm invests in early-stage companies in the biotech therapeutics, medical technology and devices, diagnostics, and healthcare IT sectors. The firm is sector and indication agnostic.

The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a China-based company that that focuses on water treatment, sludge treatment, solid waste disposal, and special pump manufacturing, is currently operating a $25M USD fund and a $200M RMB fund that focus on cleantech, hardware, healthtech, and biotechnology. In addition, the firm is also in the process of developing a new acceleration program in the USA dedicated for cleantech innovations. Unlike many other corporate VC arms that have a slow internal investment process, the firm is able to proceed quickly with their decision making process.

The firm has invested in 10 companies since its establishment in 2017 and is actively seeking investment opportunities in the sectors mentioned above. The firm will initially invest up to $1M in equity. The firm works closely with the local government in China and utilizes domestic resources to support company growth in China, but China angle is not necessary for investment. The firm is open to companies globally.

The firm invests broadly in the life sciences and healthcare sectors, including therapeutics, medical devices, and diagnostics. However, the firm will most likely not invest in healthcare IT technologies. The firm is establishing a hospital in China and is most interested in technologies that could be integrated in hospital systems. The firm is agnostic in terms of the company’s stage of development.

The firm is interested in working with companies supported by an experienced management team with strong expertise. The firm is open to acting as a lead or co-investor and is capable of bringing other regional investment groups to syndicate rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm headquartered in Europe is exclusively focused on the development of oncology therapies. The firm makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from a few hundred thousand dollars up to a couple of million dollars. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

Representative portfolio companies include: a company developing small-molecule and antibody compounds targeting tumor related immune suppression, enhanced APC function and immune cell efficacy; a company developing novel immune modulating antibody therapeutics to harness the immune system against cancer; a spin-out company of a large pharmaceutical company developing a new generation of highly selective MET kinase activity inhibitors with augmented therapeutic index; a company developing hypoxia activated pro-cytotoxic small molecules; a company developing a versatile nanoparticle platform which allows payload delivery in the tumor micro-environment, etc.

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has a several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Europe-based, global medical technology company formed by two medical device groups is actively seeking medical device investment opportunities. The firm typically invests early on in the development (series A or B) stage. The firm seeks to invest in the range of $1M-15M per company, though would pursue larger ($100M and up) deals if there were a strong rationale that would make the company an ideal, revenue-generating fit to the portfolio. The firm seeks to make 1-2 larger deals and 3-4 smaller ones within the next year and seeks investments globally.

The firm’s key focus areas are (1) neuromodulation (devices for epilepsy, obstructive sleep apnea, etc.), (2) cardiac surgery (heart valves, perfusion products), and (3) structural heart (transcatheter products for mitral, aortic, tricuspid repair and replacement). The call points that the firm targets are neurologists, ENTs; cardiac surgeons, cardiologists, and perfusionists.

The firm is not currently focused on therapeutics or lab equipment technology, though may be open to those used to assist procedures in the cardiovascular/neurostimulation space. The firm looks at both PMA and 510K devices, as it traditionally invests in PMA devices, and is now gaining an increasing interest in 510K devices.

The firm prefers experienced management teams, and may take a board or observer seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com